Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
A 2 by 2 factorial, multicenter, prospective, randomized, open-label, blinded endpoint trial.
Patients undergoing primary PCI for STEMI will be eligible. Enrolled patients will be
randomly assigned to the ticagrelor group or the clopidogrel group in a 1:1 ratio. After
emergent coronary angiography, patients who have thrombolysis in myocardial infarction (TIMI)
flow grade <2 in coronary angiogram will be randomized again, to either bolus intracoronary
injection of morphine sulfate or saline in a 1:1 ratio. Randomization will be stratified by
infarct location (anterior vs. non-anterior), and morphine use for pain control before study
enroll (for only intracoronary morphine).